aluates Reports

$ 0.0

Automative

Recombinant Non-Glycosylated Proteins Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-32K12054

Global Recombinant Non Glycosylated Proteins Biosimilars Industry Research Report Growth Trends and Competitive Analysis 2022 2028

BUY CHAPTERS

Recombinant Non-Glycosylated Proteins Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-32K12054

Report

September 2024

Pages:111

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sandoz Inc

Pfizer Inc

Teva Pahrmaceutical

Celltrion

Biocon Ltd.

Amgen Inc

Samsung Biologics

Mylan NV

Dr. Reddy’s Laboratories

STADA Arzneimittel AG

Recombinant Non-Glycosylated Proteins Biosimilars - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Recombinant Non-Glycosylated Proteins Biosimilars - Market

Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars.

The global market for Recombinant Non-Glycosylated Proteins Biosimilars was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Non-Glycosylated Proteins Biosimilars, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Recombinant Non-Glycosylated Proteins Biosimilars by region & country, by Type, and by Application.

The Recombinant Non-Glycosylated Proteins Biosimilars market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Non-Glycosylated Proteins Biosimilars.

Market Segmentation

Scope of Recombinant Non-Glycosylated Proteins Biosimilars - Market Report

Report Metric	Details
Report Name	Recombinant Non-Glycosylated Proteins Biosimilars - Market
CAGR	5%
Segment by Type:	Insulin rHGH Interferon
Segment by Application	Oncology Chronic Diseases Autoimmune Diseases Blood Disorders Growth Hormone Deficiency Infectious Diseases Other Diseases
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Non-Glycosylated Proteins Biosimilars manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Recombinant Non-Glycosylated Proteins Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Recombinant Non-Glycosylated Proteins Biosimilars in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Recombinant Non-Glycosylated Proteins Biosimilars - Market report?

Ans: The main players in the Recombinant Non-Glycosylated Proteins Biosimilars - Market are Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy's Laboratories, Stada Arzneimittel AG

What are the Application segmentation covered in the Recombinant Non-Glycosylated Proteins Biosimilars - Market report?

Ans: The Applications covered in the Recombinant Non-Glycosylated Proteins Biosimilars - Market report are Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Diseases

What are the Type segmentation covered in the Recombinant Non-Glycosylated Proteins Biosimilars - Market report?

Ans: The Types covered in the Recombinant Non-Glycosylated Proteins Biosimilars - Market report are Insulin, rHGH, Interferon

Recommended Reports

Biosimilars & Biologics

Protein & Peptide Drugs

Immunology & Therapeutics

1 Market Overview

1.1 Recombinant Non-Glycosylated Proteins Biosimilars Product Introduction

1.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Forecast

1.3 Recombinant Non-Glycosylated Proteins Biosimilars Market Trends & Drivers

1.3.1 Recombinant Non-Glycosylated Proteins Biosimilars Industry Trends

1.3.2 Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers & Opportunity

1.3.3 Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges

1.3.4 Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Players Revenue Ranking (2023)

2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue by Company (2019-2024)

2.3 Key Companies Recombinant Non-Glycosylated Proteins Biosimilars Manufacturing Base Distribution and Headquarters

2.4 Key Companies Recombinant Non-Glycosylated Proteins Biosimilars Product Offered

2.5 Key Companies Time to Begin Mass Production of Recombinant Non-Glycosylated Proteins Biosimilars

2.6 Recombinant Non-Glycosylated Proteins Biosimilars Market Competitive Analysis

2.6.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Recombinant Non-Glycosylated Proteins Biosimilars Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Insulin

3.1.2 rHGH

3.1.3 Interferon

3.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type

3.2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, by Type (2019-2030)

3.2.3 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Oncology

4.1.2 Chronic Diseases

4.1.3 Autoimmune Diseases

4.1.4 Blood Disorders

4.1.5 Growth Hormone Deficiency

4.1.6 Infectious Diseases

4.1.7 Other Diseases

4.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application

4.2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, by Application (2019-2030)

4.2.3 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region

5.1.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (2019-2024)

5.1.3 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (2025-2030)

5.1.4 Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

5.2.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

5.3.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

5.4.2 Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

5.5.2 South America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

5.6.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Recombinant Non-Glycosylated Proteins Biosimilars Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Recombinant Non-Glycosylated Proteins Biosimilars Sales Value

6.3 United States

6.3.1 United States Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.3.2 United States Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.4.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.5.2 China Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.5.3 China Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.6.2 Japan Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.7.2 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.8.2 Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019-2030

6.9.2 India Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

6.9.3 India Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Sandoz

7.1.1 Sandoz Profile

7.1.2 Sandoz Main Business

7.1.3 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.1.4 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.1.5 Sandoz Recent Developments

7.2 Pfizer

7.2.1 Pfizer Profile

7.2.2 Pfizer Main Business

7.2.3 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.2.4 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.2.5 Pfizer Recent Developments

7.3 Teva Pahrmaceutical

7.3.1 Teva Pahrmaceutical Profile

7.3.2 Teva Pahrmaceutical Main Business

7.3.3 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.3.4 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.3.5 Celltrion Recent Developments

7.4 Celltrion

7.4.1 Celltrion Profile

7.4.2 Celltrion Main Business

7.4.3 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.4.4 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.4.5 Celltrion Recent Developments

7.5 Biocon

7.5.1 Biocon Profile

7.5.2 Biocon Main Business

7.5.3 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.5.4 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.5.5 Biocon Recent Developments

7.6 Amgen

7.6.1 Amgen Profile

7.6.2 Amgen Main Business

7.6.3 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.6.4 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.6.5 Amgen Recent Developments

7.7 Samsung Biologics

7.7.1 Samsung Biologics Profile

7.7.2 Samsung Biologics Main Business

7.7.3 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.7.4 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.7.5 Samsung Biologics Recent Developments

7.8 Mylan

7.8.1 Mylan Profile

7.8.2 Mylan Main Business

7.8.3 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.8.4 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.8.5 Mylan Recent Developments

7.9 Dr. Reddy's Laboratories

7.9.1 Dr. Reddy's Laboratories Profile

7.9.2 Dr. Reddy's Laboratories Main Business

7.9.3 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.9.4 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.9.5 Dr. Reddy's Laboratories Recent Developments

7.10 Stada Arzneimittel AG

7.10.1 Stada Arzneimittel AG Profile

7.10.2 Stada Arzneimittel AG Main Business

7.10.3 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

7.10.4 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2019-2024)

7.10.5 Stada Arzneimittel AG Recent Developments

8 Industry Chain Analysis

8.1 Recombinant Non-Glycosylated Proteins Biosimilars Industrial Chain

8.2 Recombinant Non-Glycosylated Proteins Biosimilars Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Recombinant Non-Glycosylated Proteins Biosimilars Sales Model

8.5.2 Sales Channel

8.5.3 Recombinant Non-Glycosylated Proteins Biosimilars Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Sandoz Inc

Pfizer Inc

Teva Pahrmaceutical

Celltrion

Biocon Ltd.

Amgen Inc

Samsung Biologics

Mylan NV

Dr. Reddy’s Laboratories

STADA Arzneimittel AG

List of Tables

Table 1. Recombinant Non-Glycosylated Proteins Biosimilars Market Trends

Table 2. Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers & Opportunity

Table 3. Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges

Table 4. Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints

Table 5. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Recombinant Non-Glycosylated Proteins Biosimilars Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Recombinant Non-Glycosylated Proteins Biosimilars Product Type

Table 9. Key Companies Time to Begin Mass Production of Recombinant Non-Glycosylated Proteins Biosimilars

Table 10. Global Recombinant Non-Glycosylated Proteins Biosimilars Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (2019-2024) & (%)

Table 27. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Recombinant Non-Glycosylated Proteins Biosimilars Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2025-2030) & (US$ Million)

Table 31. Sandoz Basic Information List

Table 32. Sandoz Description and Business Overview

Table 33. Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 34. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Sandoz (2019-2024)

Table 35. Sandoz Recent Developments

Table 36. Pfizer Basic Information List

Table 37. Pfizer Description and Business Overview

Table 38. Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 39. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Pfizer (2019-2024)

Table 40. Pfizer Recent Developments

Table 41. Teva Pahrmaceutical Basic Information List

Table 42. Teva Pahrmaceutical Description and Business Overview

Table 43. Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 44. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Teva Pahrmaceutical (2019-2024)

Table 45. Teva Pahrmaceutical Recent Developments

Table 46. Celltrion Basic Information List

Table 47. Celltrion Description and Business Overview

Table 48. Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 49. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Celltrion (2019-2024)

Table 50. Celltrion Recent Developments

Table 51. Biocon Basic Information List

Table 52. Biocon Description and Business Overview

Table 53. Biocon Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 54. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Biocon (2019-2024)

Table 55. Biocon Recent Developments

Table 56. Amgen Basic Information List

Table 57. Amgen Description and Business Overview

Table 58. Amgen Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 59. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Amgen (2019-2024)

Table 60. Amgen Recent Developments

Table 61. Samsung Biologics Basic Information List

Table 62. Samsung Biologics Description and Business Overview

Table 63. Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 64. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Samsung Biologics (2019-2024)

Table 65. Samsung Biologics Recent Developments

Table 66. Mylan Basic Information List

Table 67. Mylan Description and Business Overview

Table 68. Mylan Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 69. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Mylan (2019-2024)

Table 70. Mylan Recent Developments

Table 71. Dr. Reddy's Laboratories Basic Information List

Table 72. Dr. Reddy's Laboratories Description and Business Overview

Table 73. Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 74. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Dr. Reddy's Laboratories (2019-2024)

Table 75. Dr. Reddy's Laboratories Recent Developments

Table 76. Stada Arzneimittel AG Basic Information List

Table 77. Stada Arzneimittel AG Description and Business Overview

Table 78. Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions

Table 79. Revenue (US$ Million) in Recombinant Non-Glycosylated Proteins Biosimilars Business of Stada Arzneimittel AG (2019-2024)

Table 80. Stada Arzneimittel AG Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Recombinant Non-Glycosylated Proteins Biosimilars Downstream Customers

Table 84. Recombinant Non-Glycosylated Proteins Biosimilars Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Recombinant Non-Glycosylated Proteins Biosimilars Product Picture

Figure 2. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 4. Recombinant Non-Glycosylated Proteins Biosimilars Report Years Considered

Figure 5. Global Recombinant Non-Glycosylated Proteins Biosimilars Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Non-Glycosylated Proteins Biosimilars Revenue in 2023

Figure 7. Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Insulin Picture

Figure 9. rHGH Picture

Figure 10. Interferon Picture

Figure 11. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Oncology

Figure 14. Product Picture of Chronic Diseases

Figure 15. Product Picture of Autoimmune Diseases

Figure 16. Product Picture of Blood Disorders

Figure 17. Product Picture of Growth Hormone Deficiency

Figure 18. Product Picture of Infectious Diseases

Figure 19. Product Picture of Other Diseases

Figure 20. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 21. Global Recombinant Non-Glycosylated Proteins Biosimilars Sales Value Market Share by Application, 2023 & 2030

Figure 22. North America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 23. North America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 24. Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 25. Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 26. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 27. Asia Pacific Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 28. South America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 29. South America Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 30. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 31. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 32. Key Countries/Regions Recombinant Non-Glycosylated Proteins Biosimilars Sales Value (%), (2019-2030)

Figure 33. United States Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 34. United States Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 35. United States Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 36. Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 37. Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 38. Europe Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 39. China Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 40. China Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 41. China Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 42. Japan Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 43. Japan Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 44. Japan Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 45. South Korea Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 46. South Korea Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 47. South Korea Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 48. Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 49. Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 50. Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 51. India Recombinant Non-Glycosylated Proteins Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 52. India Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 53. India Recombinant Non-Glycosylated Proteins Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 54. Recombinant Non-Glycosylated Proteins Biosimilars Industrial Chain

Figure 55. Recombinant Non-Glycosylated Proteins Biosimilars Manufacturing Cost Structure

Figure 56. Channels of Distribution (Direct Sales, and Distribution)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Recombinant Non Glycosylated Protein Market Research Report 2025

Glycosylated Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Glycosylated Protein Market Research Report 2025

Recombinant Protein Therapeutics Market

Global Filgrastim and Biosimilars Market Research Report 2024

Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biosimilar Drug Market

Recombinant Protein Drugs Market

Global Human Recombinant Growth Factors Market Research Report 2025

Global Recombinant Protein Drug R D Market Research Report 2024

Global Cetuximab Biosimilar Market Research Report 2025

Global Recombinant Growth Factors Market Research Report 2025

Recombinant Human Chorionic Gonadotropin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions